Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to understand oncology financial market dynamics and wisely build investment portfolios comprised of company stocks that fight Liver Cancer.
The Liver Cancer Therapeutics Market size is estimated at USD 3.66 billion in 2024, and is expected to reach USD 8.67 billion by 2029, growing at a compound annual growth rate (CAGR) of 18.76% during the forecast period (2024-2029).
Liver cancer ranks ninth among cancers in women and fifth among cancers in males. The major factors driving the market growth include the rising burden of liver cancer, increasing research and development investments for the development of novel therapies, and government initiatives to increase cancer awareness.
Hepatocellular carcinoma (HCC) is a common form of liver cancer that occurs in people suffering from chronic liver diseases like cirrhosis. It is mainly brought on by hepatitis B virus (HBV) infection, which accounts for about 50% of cases.
North America is expected to hold a significant share of the studied market owing to the rising incidence of liver cancer in the region, the presence of key market players, and the launch of novel products coupled with various investments, as well as funding for liver cancer therapeutics development.
For additional information on Liver Cancer, please review the video by Mayo Clinic.